Background: Treatment options for hepatitis C have developed rapidly in the past decade. The current treatment of choice is a combination of pegylated-interferon-alpha (PEG-IFN-alpha) and ribavirin. With the development of more therapy options, patients who failed in prior therapy hope to clear hepatitis C virus by undergoing a more effective retreatment regime. In this report, we investigated response rates to combination therapy [standard IFN-alpha or PEG-IFN-alpha and ribavirin] in patients who relapsed or failed in prior therapy.
Methods: Ninety-three patients were included in this retrospective study. All patients failed to previous IFN-alpha monotherapy (n=55) or to a combination of standard IFN-alpha and ribavirin (n=38). Fifty-nine patients were nonresponders and 34 were relapsers. Thirty-five patients were retreated with standard IFN-alpha plus ribavirin and 58 received PEG-IFN-alpha combination therapy.
Results: Sustained virologic response (SVR) was induced in 31% of all patients. The highest SVR rate (58%) was observed in relapsers to standard IFN-alpha combination therapy who were retreated with PEG-IFN-alpha combination therapy. The SVR rate in relapsers to standard IFN-alpha monotherapy who received a standard IFN-alpha combination therapy was 50%. Relapsers responded in a significantly higher proportion to retreatment than nonresponders (56% vs. 17%, P<0.001). Relapse to previous therapy was identified as an independent predictor for therapy response. The lowest SVR rate was observed in nonresponders to standard IFN-alpha combination therapy who were retreated with PEG-IFN-alpha combination therapy (1/26; 4%).
Conclusions: In relapsers, retreatment with the most effective therapy regime to date a combination of PEG-IFN-alpha and ribavirin, is promising. However, retreatment with PEG-IFN-alpha combination therapy in nonresponders to standard IFN combination therapy is not effective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1478-3231.2007.01508.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of increased serum I-309 with phenotypes, disease activity, and cytokine pattern in primary Sjögren's syndrome.
Clin Rheumatol
January 2025
Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People's Hospital, Taizhou, Zhejiang, China.
The aim of this study was to determine serum I-309 levels in primary Sjögren's syndrome (pSS) patients, as well as the association with disease phenotype, systemic activity, and T helper cell-related cytokines. A total of 58 pSS patients and 30 healthy controls (HC) were enrolled in this study. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-9, IL-13, IL-17, IL-22, IL-23, tumor-necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IFN-α, and IFN-β were measured with multiplex immunoassay.
View Article and Find Full Text PDFIFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment.
J Cancer
October 2024
Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Bladder cancer (BCa) is the 10th most prevalent cancer globally. Neoadjuvant therapy has become the standard treatment for muscle-invasive bladder cancer, yet the pathologic complete response rate for patients is only approximately 35%. However, the mechanisms underlying neoadjuvant therapy resistance in bladder cancer patients remain unclear.
View Article and Find Full Text PDFMaternal and Foetal Outcomes of Newly Diagnosed Chronic Myeloid Leukemia During Pregnancy and its Long-Term Impact.
Indian J Hematol Blood Transfus
October 2024
Department of Clinical Haematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012 India.
Article Synopsis
- Diagnosing Chronic Myeloid Leukemia (CML) during pregnancy poses significant challenges, especially in low- and middle-income countries, with limited management data available.
- The study investigated outcomes for female patients diagnosed with CML-CP during pregnancy, analyzing medical records from 2002 to 2022, highlighting various pregnancy outcomes and treatment strategies.
- Among the thirteen patients examined, outcomes included five elective terminations, five pre-term deliveries, and three full-term deliveries, with a median follow-up showing that most maintained major molecular remission, illustrating the need for coordinated care between haematologists and obstetricians.
Single-cell transcriptome profiling identifies the activation of type I interferon signaling in ossified posterior longitudinal ligament.
Front Med
December 2024
Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, State Key Laboratory of Molecular Oncology and International Cancer Institute, Peking University Health Science Center, Beijing, 100191, China.
Article Synopsis
- Ossification of the posterior longitudinal ligament (OPLL) involves abnormal bone formation in spinal ligaments and is a major cause of myelopathy, particularly in Asian populations.
- Research using single-cell RNA sequencing revealed that type I interferon (IFN) signaling is active in ossified ligaments of individuals with OPLL.
- Increasing IFN-β levels promotes bone cell development, while blocking the IFNAR1 receptor suppresses this process, suggesting that targeting the type I IFN pathway could help prevent OPLL.
Immunological sub-phenotypes and response to convalescent plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial.
Ann Intensive Care
October 2024
Department of Intensive Care Medicine, Mons-Hainaut Regional Hospital, Mons, Belgium.
Background: Convalescent plasma (CP) reduced the mortality in COVID-19 induced ARDS (C-ARDS) patients treated in the CONFIDENT trial. As patients are immunologically heterogeneous, we hypothesized that clusters may differ in their treatment responses to CP.
Methods: We measured 20 cytokines, chemokines and cell adhesion markers using a multiplex technique at the time of inclusion in the CONFIDENT trial in patients of centers having accepted to participate in this secondary study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!